Navigation Links
Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics
Date:9/10/2012

NEW YORK, Sept. 10, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics

http://www.reportlinker.com/p0963390/Epigenomics-Present-and-Future-Applications-for-Pharmaceuticals-and-Diagnostics.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

"Mabs" and molecular tests are among the growth industries of pharmaceuticals and diagnostics, but they may have competition long-term from an unexpected source. Epigenomics is a potential game-changer in the clinical therapeutics market and significant in testing as well. It refers to technologies involving changes in genetic material that find their origins in causes other than base pairs alterations in the DNA of the host. Examples of such changes include DNA methylation and histone acetylation, both of which have been known for many years to cause changes in gene expression. This report Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics describes the progress that has been made in our understanding of the basic science of epigenomics and considers the practical accomplishments being reported by the private sector.

Epigenomics constitutes a challenge to the long held paradigm of DNA base pair sequences as the prime determinant of the phenotype. Because of this profound intellectual shift, a vast new area of biological investigation is rapidly unfolding. This presents significant opportunities for understanding disease processes and developing the means of combating them.

Epigenomic Mechanisms Discussed in the report include:

  • DNA methylation
  • Histone Acetylation
  • Histone Phosphorylation
  • Methylation
  • Sumoylation
  • Histone "chaperones"
  • MicroRNAs (miRNAs)

The examination of many diseases in a completely new light means there exist a wealth of opportunities to develop new diagnostic and therapeutic approaches. At the same time it means that outdated concepts will have to be revised. This report looks at the science behind epigenomics and deals with opportunities for product development based on epigenetic technologies and the outlook for the future in this exciting area of pharmaceutical technologies. In doing so, the report provides:

  • Discussion of the Basic Science and Mechanisms Behind Epigenomics
  • Activities of Top Companies in the Market
  • Interviews with Researchers and Private Sector Leaders
  • Market Estimates for Current Epigenomic Drugs and Forecast to 2017
  • Market Estimates for Current Epigenomic Diagnostics and Comparison to Next Gen Cancer Diagnostics Market
  • Analyst Conclusions Regarding the Future Market for Epigenomics
  • Key Healthcare Segments Impacted by Epigenomics
  • Examples of Clinically Relevant Epigenetic Biomarkers
  • Currently Approved Epigenomic Drugs
  • Epigenetic Drivers of Disease
  • Pharmaceutical R&D: A Need for Better Returns
  • Look at Applications in Alzheimer's Disease, Mental Illness, Auto-Immune Diseases, Autism and Cardiovascular Disease

CHAPTER ONE: EXECUTIVE SUMMARY

  • The Basic Science of Epigenetics- Basic Life Science R&D
  • Epigenetics and Diagnostics
  • Outlook for epigenetics R&D

CHAPTER TWO: THE BASIC SCIENCE OF EPIGENETICS

  • A New Look at Health and Disease.
    • Lamarck
    • Weissmann
  • The History of Epigenetics to the Present
  • What This Report Covers
  • What is Epigenetics?
    • The concept.
  • A New Level of Challenge
  • Implications for the Healthcare industry
  • The Big Picture: An interview with Dr. Michael Skinner
  • The Molecular Biology of Epigenetic Control Mechanisms
    • DNA methylation
  • Histone acetylation and other modifications
    • Complex; not well understood
    • Histone Acetylation
    • Histone phosphorylation
    • Methylation
    • Sumoylation
    • Histone "chaperones"
    • MicroRNAs (miRNAs)
  • Summary, Conclusions

CHAPTER THREE: EPIGENETIC AND DIAGNOSIS

  • Epigenetic drivers of disease
    • Epigenetics and DNA methylation
  • Role of histones
  • Early cancer diagnosis
  • Methylation Markers
    • Challenges in the Identification of Epigenetic Involvement in Non-Cancerous Diseases
  • Summary, Conclusions

CHAPTER FOUR: MARKET DRIVERS

  • Epigenetics and Therapeutics: Market by major diseases
  • Cancers
    • Hypo/Hypermethylation
  • Anti-Cancer Therapy
    • Covalent histone modifications
    • Aberrant miRNA expression
    • Autoimmune dysfunction
    • Cardiovascular
  • Mental Disorders
    • A classic Vision of Mental Illness
    • Schizophrenia
    • Bipolar disorder
    • Autism
    • Alzheimer's Disease
    • Spinal muscular Atrophy (SMA)
    • Parkinson's Disease
    • Imprinting Disorders
    • Praeder-Willi Syndrome
    • Angelman Syndrome
    • Beckwith-Wiedemann Syndrome
  • Fragile X Syndrome
  • Friedreich's Ataxia
  • Concluding on a Cautionary Note

CHAPTER FIVE: COMPANIES ACTIVE IN EPIGENOMICS

  • Diagnostic companies
  • Enzo Life Sciences
  • Epigenomics AG
    • Epiontis
  • Exact Sciences
    • Illumina
    • Novus Biologicals
    • Oncomethylome Sciences
    • Valirx
    • Volition Singapore
  • Therapeutic Companies
    • Acetylon Pharmaceuticals
    • Acylin Therapeutics
    • CellCentric
    • Celdex
    • Celgene
    • Celzome (UK/DE)
    • Chroma Therapeutics
    • Constellation Pharma
    • Eisai Co. Ltd
    • Epitherapeutics
    • EpiZyme
    • Methyl Gene
    • Novartis:
    • Orion
    • RaNA Therapeutics
    • Syndax Pharmaceuticals Inc.
    • ValiRX (UK)
  • Epigenetics research products supply companies
    • Active Motif
    • Diagenode
    • Epigentek
    • Life Technologies
    • Qiagen
    • Sigma-Aldrich
    • Zymo Research Products
  • Summary, Conclusions

CHAPTER SIX: OUTLOOK FOR THE EPIGENETICS MARKET

  • Growth in World Markets; Overall
  • Dim Prospects for Pharma: How to Upend them
  • Upsides, Opportunities: A huge market for epigenetic-based cancer treatments.
  • The IVD market
  • The Overall IVD Market
  • Specific Epigenetic IVD market breakdown
  • Personalized medicine and epigenetics
  • Industry Challenges and Strategic Recommendations
  • Competitive landscape
  • Total Epigenetics Market 2008-2017
  • Market Drivers and Restraints
  • Market Forecasts and Competitive Analysis
    • Revenue Forecasts
    • Competitive Structure
    • Competitive Metrics
    • Market Share Analysis: Product segments
  • WW Epigenetic Market 2008-2017
    • North America
    • EU
    • Japan
    • Asia Pacific
    • Ominous signs from China
  • The Way Forward
    • South America
  • Summary, Conclusions

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1:The most common epigenetic alterations

CHAPTER TWO: THE BASIC SCIENCE OF EPIGENETICS

  • Figure 2-1 Timeline of epigenetic discoveries ourtesy Constellation Pharma
  • Table 2-1 The most common epigenetic alterations
  • Figure 2-2 Agouti Mice
  • Figure 2-3 Classic DNA methylation reaction
  • Figure 2-4 The molecule 5-hydroxymethylcytosine
  • Figure 2-5 DNA molecule wrapped twice around a Hisotne Octamer to make a Nucleosome
  • Table 2-2 Varieties of histone modification and their properties
  • Figure 2-6 Acetylation and deacetylation of lysene residues
  • Figure 2-7 Shilatifard A. 2008

CHAPTER THREE: EPIGENETIC AND DIAGNOSIS

  • Table 3-1: Examples of Clinically Relevant Epigenetic Biomarkers

CHAPTER FOUR: MARKET DRIVERS

  • Table 4-1: Currently FDA-approved Epigenetic-Based Drugs
  • Figure 4-1: Structures of (A) 5-aza 2'-deoxycytidine (5 aza –dC, decitabine) and (B) zebularine
  • Figure 4-2: U.S. FDA-approved Epigenetic-Acting Drugs
  • Table 4-3: Prevalance of Autism as a Function Time, 200-2008
  • Table 4-4: Current Autism Therapies
  • Figure 4-3: Map of the 11p15 imprinted region

CHAPTER FIVE: COMPANIES ACTIVE IN EPIGENOMICS

  • Table 5-1: Some Important Epigenetics Diagnostics Companies
  • Table 5-2: The Epigenetics Land Grab: R&D from Major Pharma Companies
  • Figure 5-2: JUN/EPIZYME An Example of one of Epizyme's inhibitors interacting with an epigenetic enzyme
  • Figure 5-3: Structure of LBH589 (panobinostat)
  • Figure 5-4: Action of Panbinostat
  • Figure 5-5: Structure of Entinostat

CHAPTER SIX: OUTLOOK FOR THE EPIGENOMICS MARKET

  • Table 6.1:GNP Growth by Country, Region
  • Table 6.2: Conflicting Worldwide Economic Drivers And Their Impact On Epigenomics Technologies
  • Figure 6.1: Vast Expenditures, Poor Returns
  • Table 6.3: Guidelines For A New Stage Of Drug Development
  • Table 6.4: Epigenomics Therapeutics Market, 2011 and 2017 (millions)
  • Table 6.5: Global Pharma Market, 2010 and 2015 (billions)
  • Figure 6.2: Epigenomic Drug Market, 2011 and 2017
  • Table 6.6: FDA-Approved Epigenetic Anti-Cancer Agents
  • Figure 6.3: Epigenomics Diagnostics Market, 2010 and 2015
  • Table 6.7: Next Gen Cancer Diagnostics Market, 2010-2015
  • Table 6.8: Epigenomics in Cancer Diagnostics, 2010-2015
  • Table 6.9: Total IVD Market 2007-2011
  • Table 6.10: Some Current Epigenomics Research Goals
  • Table 6.11: Cancer Diagnostics Market
  • Table 6.12: Some Major Companies And Their Activities
  • Figure 6.4: Publications on Epigenomics and Cardiovascular Disease
  • Table 6.13: Takeda regional Portfolio Blance As a Bellweather

To order this report:

Pathology Industry: Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics

Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
2. Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference
3. Covance to Present at the Morgan Stanley Global Healthcare Conference
4. Amgen To Present At The Morgan Stanley Global Healthcare Conference
5. Champions Oncology to Present at Rodman & Renshaw Conference
6. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
7. Cumberland Pharmaceuticals to Present at the UBS Global Life Sciences Conference in New York
8. PDL BioPharma to Present at Upcoming Investor Conferences
9. CVS Caremark to Present at Morgan Stanley Global Healthcare Conference
10. GP Strategies to Present at the BMO Capital Markets 12th Annual Back to School Education Conference
11. Depomed To Present At Morgan Stanley 2012 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... technology to revolutionize the emergency ambulance transport experience for the millions of people ... how Uber has disrupted the taxi industry through the use of technology. Now, ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
Breaking Medicine News(10 mins):